Apolipoprotein B Antisense Inhibition -Update on Mipomersen

E-ISSN： 1873-4286|19|17|3132-3142

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.17, 2013-05, pp. : 3132-3142

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′- O -Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

By Yu Rosie Z.

Clinical Pharmacokinetics, Vol. 48, Iss. 1, 2009-01 ,pp. : 39-50

Adis International

Access to resources Recommend Favorite

Mipomersen

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 4, 2010-08 ,pp. : 271-279

Adis International

Access to resources Recommend Favorite

Apolipoprotein B and apolipoprotein E genotypes and sporadic holoprosencephaly

American Journal of Medical Genetics, Vol. 108, Iss. 1, 2002-02 ,pp. : 75-77

John Wiley & Sons Inc

Access to resources Recommend Favorite

Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1562-1570

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Human Telomerase by Antisense Oligonucleotides and Ribozymes: An Update

Medicinal Chemistry Reviews - Online, Vol. 1, Iss. 4, 2004-10 ,pp. : 413-417

Bentham Science Publishers

Access to resources Recommend Favorite